Moderna, Inc. (NASDAQ:MRNA) Logo

Moderna (NASDAQ:MRNA) Receives a Downgrade

Moderna (NASDAQ:MRNA) shares were lowered by BidaskScore to a “Hold” rating in a report sent to investors and clients on Friday, 6 December.

The stock decreased 8.24% or $1.7 during the last trading session, reaching $18.94. About 3.54M shares traded or 48.10% up from the average. Moderna, Inc. (NASDAQ:MRNA) has 0.00% since December 7, 2018 and is . It has by 0.00% the S&P500.

Analysts await Moderna, Inc. (NASDAQ:MRNA) to report earnings on March, 11. After $-0.37 actual earnings per share reported by Moderna, Inc. for the previous quarter, Wall Street now forecasts 2.70 % negative EPS growth.

Moderna, Inc. develops medicines based on messenger RNA . The company has market cap of $6.30 billion. The Company’s pipeline includes development candidates for mRNA vaccines and therapies for use in various therapeutic areas comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. It currently has negative earnings. The firm was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018.

More notable recent Moderna, Inc. (NASDAQ:MRNA) news were published by: which released: “Moderna, Inc. (MRNA) CEO Stéphane Bancel on Q3 2019 Results – Earnings Call Transcript – Seeking Alpha” on November 08, 2019, also with their article: “Moderna: Undervalued As The Promising Pipeline Awaits Collaborations – Seeking Alpha” published on November 21, 2019, published: “Sell-siders like Tela Bio in premarket analyst action – Seeking Alpha” on December 03, 2019. More interesting news about Moderna, Inc. (NASDAQ:MRNA) were released by: and their article: “Is CRISPR Therapeutics the Best Gene-Editing Stock Right Now? – Nasdaq” published on November 26, 2019 as well as‘s news article titled: “5 “Strong Buy” Biotech Stocks With More Than 80% Upside – Nasdaq” with publication date: November 27, 2019.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Source link